Quantitative estimation of riluzole in human plasma by LC-ESI-MS/MS and its application to a bioequivalence study

Analytical and Bioanalytical Chemistry

Volumn 398, Issue 3, 2010, Pages 1367-1374

  Chandu, Babu Rao ^e   Nama, Sreekanth ^a,d   Kanala, Kanchanamala ^b   Challa, Balasekhara Reddy ^b   Shaik, Rihana Parveen ^c   Khagga, Mukkanti ^d  

^a JIMMA UNIVERSITY   (Ethiopia)

^b Nalanda Educational Society   (India)

^c MEIJI DAIRIES CORPORATION   (Japan)

^d JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^e NONE

Author keywords

Bioequivalence study; Liquid chromatography; Liquid liquid extraction; Mass spectrometry; Pharmacokinetic study; Riluzole

Indexed keywords

BIOEQUIVALENCE STUDY; CALIBRATION CURVES; CONCENTRATION RANGES; HUMAN PLASMAS; INTERNAL STANDARDS; ISOCRATIC MOBILE PHASE; LC-ESI-MS/MS; LIMIT OF QUANTIFICATIONS; LIQUID-LIQUID EXTRACTION; MULTIPLE-REACTION MONITORING MODES; PHARMACOKINETIC STUDY; QUANTITATIVE ESTIMATION; RILUZOLE; TANDEM MASS SPECTROMETRY; VALIDATED METHODS;

COLUMN CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; ISOTOPES; MASS SPECTROMETRY; PHARMACOKINETICS; PLASMA (HUMAN); PLASMAS; SOLVENT EXTRACTION;

LIQUIDS;

AMINO ACID RECEPTOR BLOCKING AGENT; RILUZOLE;

BLOOD; CALIBRATION; CONFERENCE PAPER; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; METHODOLOGY; PHARMACOKINETICS; REPRODUCIBILITY; STANDARD; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

CALIBRATION; CHROMATOGRAPHY, LIQUID; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; LIMIT OF DETECTION; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RILUZOLE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY;

EID: 77957825928     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-010-4034-8     Document Type: Conference Paper

References (12)

1. T Araki T Kumagai M Matsubara T Ido Y Imai Y Itoyama Metab 2000 Brain Dis 15 193 1:CAS:528:DC%2BD3MXps1CjtQ%3D%3D
2. ME Gurney FB Cutting P Zhai A Doble CP Taylor PK Andrus ED Hall 1996 Ann Neurol 39 147 1:CAS:528:DyaK28XitlKktLw%3D 10.1002/ana.410390203
3. C Malgouris M Daniel A Doble 1994 Neurosci Lett 177 95 1:CAS:528:DyaK2cXmsVGqs7w%3D 10.1016/0304-3940(94)90053-1
4. YG Sherki E Melamed D Offen 2003 Brain Res 989 196 10.1016/S0006-8993(03) 03343-2
5. M Colovic E Zennaro S Caccia 2004 J Chromatogr B 803 2 305 1:CAS:528:DC%2BD2cXivVCkt7Y%3D 10.1016/j.jchromb.2004.01.004
6. A Maltese F Maugeri F Drago C Bucolo 2005 J Chromatogr B 817 2 331 1:CAS:528:DC%2BD2MXosF2hsA%3D%3D 10.1016/j.jchromb.2004.11.053
7. HJM Van Kan M Spieksma GJ Groeneveld J van den Sastre Torano LH Berg H Guchelaar 2004 J Biomed Chromatogr 18 9 723 10.1002/bmc.384
8. Wang Xue-Ding Chan Eli Chen Xiao Liao Xiao-Xing Tang Cheng Zhou Zhi-Wei Huang Min Zhou Shu-Feng 2007 J Pharm Biomed Anal 44 1 224 10.1016/j.jpba.2007. 01.009
9. K Sivakumari B Satyanarayana A Nageswari Shiv raj 2009 Chromatographia 69 5-6 513 1:CAS:528:DC%2BD1MXisVKqu7s%3D 10.1365/s10337-008-0916-8
10. FDA (2001) Guidance for industry: bioanalytical method validation, May 2001. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Rockville, MD
11. FDA (2002) Guidance for industry: food-effect bioavailability and fed bioequivalence studies,December 2002. US Department of Health and Human services Food and Drug Administration Centre for Drug Evaluation and research (CDER), Rockville, MD.
12. FDA (2003) Guidance for industry: bioavailability and fed bioequivalence studies for orally administered drug products-general considerations, March 2003. US Department of Health and Human services Food and Drug Administration Centre for Drug Evaluation and research (CDER), Rockville, MD